Second Spring? Coverage Expansion Fuels Big Pharma China Growth But '4+7' Impact Lingers

AstraZeneca, Novartis and Roche deliver north of 20% sales growth in China again, driven by expanded reimbursement coverage and new product launches, but some clouds are on the horizon over falling sales due to the impact of the expanding “4+7” centralized procurement scheme.

China growth
Big Pharma Sees Continued Strong China Growth • Source: Shutterstock

Roche's third-quarter earnings show that sales in its International region, which includes China, grew 20% in the period, boosted by an expansion in coverage for its anticancer drugs.

The stellar performance was “mainly driven by significantly increased numbers of patients benefiting from Roche cancer drugs in China with strong sales of Herceptin (trastuzumab), Avastin (bevacizumab) and MabThera/Rituxan (rituximab), as well as the uptake of Perjeta (pertuzumab) and Alecensa (alectinib)”, said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia